Effect of switching from intramuscular interferon β-1a to oral fingolimod on time to relapse in patients with relapsing-remitting multiple sclerosis enrolled in a 1-year extension of TRANSFORMS

Contemporary Clinical Trials

Volumn 41, Issue , 2015, Pages 69-74

  Meng, Xiangyi ^a   Chin, Peter S ^a   Hashmonay, Ron ^a   Zahur Islam, M ^a   Cutter, Gary ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Disease modifying therapy; Fingolimod; Interferon beta; Modeling; Multiple sclerosis; Relapse; Treatment switch

Indexed keywords

BETA1A INTERFERON; FINGOLIMOD; IMMUNOLOGICAL ADJUVANT; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; CHRONOTHERAPY; DISEASE DURATION; DRUG SUBSTITUTION; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; POST HOC ANALYSIS; PREDICTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; SENSITIVITY ANALYSIS; THERAPY EFFECT; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; STATISTICAL MODEL; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; ADULT; DOUBLE-BLIND METHOD; DRUG SUBSTITUTION; FEMALE; FINGOLIMOD HYDROCHLORIDE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAMUSCULAR; INTERFERON BETA-1A; LINEAR MODELS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84922262881     PISSN: 15517144     EISSN: 15592030     Source Type: Journal    
DOI: 10.1016/j.cct.2014.12.011     Document Type: Article

References (21)

1. Baumhackl U. The search for a balance between short and long-term treatment outcomes in multiple sclerosis. J Neurol 2008, 255:75-83.
2. Goodin D.S., Frohman E.M., Garmany G.P., Halper J., Likosky W.H., Lublin F.D., et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002, 58:169-178.
3. Keegan B.M. Therapeutic decision making in a new drug era in multiple sclerosis. Semin Neurol 2013, 33:5-12.
4. Goodin D.S., Frohman E.M., Garmany G.P., Halper J., Likosky W.H., Lublin F.D., et al. Supplementary material to: Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002, 58:169-178.
5. Gold R., Kappos L., Arnold D.L., Bar-Or A., Giovannoni G., Selmaj K., et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012, 367:1098-1107.
6. O'Connor P., Wolinsky J.S., Confavreux C., Comi G., Kappos L., Olsson T.P., et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011, 365:1293-1303.
7. Wolinsky J.S. The use of glatiramer acetate in the treatment of multiple sclerosis. Adv Neurol 2006, 98:273-292.
8. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 1993, 43:655-661.
9. Kappos L., Radue E.W., O'Connor P., Polman C., Hohfeld R., Calabresi P., et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010, 362:387-401.
10. Cohen J.A., Barkhof F., Comi G., Hartung H.P., Khatri B.O., Montalban X., et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010, 362:402-415.
11. Polman C.H., O'Connor P.W., Havrdova E., Hutchinson M., Kappos L., Miller D.H., et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006, 354:899-910.
12. Confavreux C., Li D.K., Freedman M.S., Truffinet P., Benzerdjeb H., Wang D., et al. Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5years. Mult Scler 2012, 18:1278-1289.
13. Khatri B., Barkhof F., Comi G., Hartung H.P., Kappos L., Montalban X., et al. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol 2011, 10:520-529.
14. Theodore Phillips J., Fox E., Selmaj K., Raghupathi K., Yuan H., Novas M., et al. Safety and tolerability of oral BG-12 (dimethyl fumarate) in relapsing-remitting multiple sclerosis (RRMS): interim results from ENDORSE extension study. Neurology 2013, 80:P01.162.
15. Branson M., Whitehead J. Estimating a treatment effect in survival studies in which patients switch treatment. Stat Med 2002, 21:2449-2463.
16. Polman C.H., Reingold S.C., Edan G., Filippi M., Hartung H.P., Kappos L., et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005, 58:840-846.
17. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33:1444-1452.
18. Khatri B.O., Pelletier J., Kappos L., Hartung H.P., Comi G., Barkhof F., et al. Effect of fingolimod on relapse rate by prior treatment status and reason for discontinuation: TRANSFORMS subgroup analysis. American Neurological Association 136th Annual Meeting. San Diego, CA 2011.
19. Cohen J.A., Barkhof F., Comi G., Izquierdo G., Khatri B., Montalban X., et al. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. J Neurol 2013, 260:2023-2032.
20. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 1995, 45:1277-1285.
21. Johnson K.P., Ford C.C., Lisak R.P., Wolinsky J.S. Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data. Acta Neurol Scand 2005, 111:42-47.